MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
PD-L1 Testing and CPS Interpretation in HNSCC
HNSCC /
KEYTRUDA /
Training and Resources /
Root /

Click to download for more information on PD-L1 Testing and CPS Interpretation in HNSCC

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Download this leaflet for more information on PD-L1 Testing and CPS Scoring in HNSCC

Abbreviations: CPS, combined positive score; HNSCC, head and neck squamous cell carcinoma;

More information about KEYTRUDA® (pembrolizumab) in first-line Head & Neck Squamous Cell Carcinoma:

Visit product page

PDF, 1.15 MB

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-OHN-00191 | Date of Preparation: August 2020